D-0226-2015 Class II Terminated

Recalled by Oregon Compounding Centers, Inc. dba Creative Compounds — Wilsonville, OR

FDA drug recall D-0226-2015 was initiated by Oregon Compounding Centers, Inc. dba Creative Compounds on October 6, 2014 and is designated Class II. Reason for recall: Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to st… The recall status is terminated (terminated June 30, 2015). Affected quantity: 2 syringes.

Recall Details

Product Type
Drugs
Report Date
November 12, 2014
Initiation Date
October 6, 2014
Termination Date
June 30, 2015
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2 syringes

Product Description

TRIESENCE, 8mg/2.0mL, Injectable, 0.2 mL plastic syringe, RX, Creative Compounds, Wilsonville, OR 97070

Reason for Recall

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

Distribution Pattern

Oregon, Washington

Code Information

Lot #: 20140909@6, discard date: 10/24/2014